Details of the Drug Reposition

General Information of This Drug (ID: DM1YVZT)

• Drug Name: Rituximab (DM1YVZT)
• Drug Type: Antibody

Information on Drug Reposition of This Drug

17 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Lymphosarcoma	DISGYV3F	N.A.	Approved	[1]
Leukemia	DISNAKFL	N.A.	Approved	[2]
Testicular lymphoma	DISC2M2N	N.A.	Approved	[3]
Hepatosplenic T-cell lymphoma	DIS7KMY9	N.A.	Approved	[4]
Splenic marginal zone lymphoma	DISCGTZY	N.A.	Approved	[5]
Small intestine lymphoma	DISDOS6S	N.A.	Approved	[6]
Central nervous system non-hodgkin lymphoma	DISHGM86	N.A.	Approved	[7]
MALT lymphoma	DIS1AVVE	N.A.	Approved	[8]
Lymphoproliferative syndrome	DISMVL8O	N.A.	Approved	[9]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified	DIS5OHQF	N.A.	Approved	[10]
Prolymphocytic leukaemia	DISDPPHX	2A82.1	Approved	[11]
Nodal marginal zone lymphoma	DIS7MP4T	2A85.0	Approved	[12]
Large granular lymphocytic leukemia	DISHOPPI	2A90.1	Approved	[13]
Non-hodgkin lymphoma	DISS2Y8A	2B33.5	Approved	[14]
Idiopathic thrombocytopenic purpura	DISFKGJU	3B64.10	Approved	[15]
Lupus nephritis	DISCVGPZ	4A40.0Y	Approved	[16]
Eosinophilic granulomatosis with polyangiitis	DIS7ITOG	4A44.A2	Approved	[17]

1 Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Pemphigus vulgaris	DISENR62	EB40	Phase 3	[18]

1 Discontinued in Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Rheumatoid arthritis	DISTSB4J	FA20	Discontinued in Phase 3	[19]

1 Discontinued in Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Metastatic melanoma	DISSL43L	2E2Z	Discontinued in Phase 2	[20]

1 Investigative Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
B-cell neoplasm	DISVY326	N.A.	Investigative	[21]

References

• [1] Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev. 1999;18(4):465-71.
• [2] Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006 Apr 1;106(7):1569-80.
• [3] First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol. 2011 Jul 10;29(20):2766-72.
• [4] Coexistent hairy cell leukaemia and hepatosplenic T-cell lymphoma: a case report. Diagn Pathol. 2014 Mar 12;9:58.
• [5] Treatment of splenic marginal zone lymphoma. Best Pract Res Clin Haematol. 2017 Mar-Jun;30(1-2):139-148.
• [6] Metachronous primary cancer of the tongue and malignant lymphoma of the small intestine: A case report. Medicine (Baltimore). 2021 Feb 19;100(7):e24806.
• [7] How we treat primary central nervous system lymphoma. ESMO Open. 2021 Aug;6(4):100213.
• [8] Diagnosis and Treatment for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. J Clin Med. 2022 Dec 23;12(1):120.
• [9] Autoimmune lymphoproliferative syndrome: A disorder of immune dysregulation. Autoimmun Rev. 2023 Nov;22(11):103442.
• [10] A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
• [11] B and T cell prolymphocytic leukaemia. Best Pract Res Clin Haematol. 2019 Sep;32(3):217-228.
• [12] Nodal marginal zone lymphoma. Leuk Lymphoma. 2014 Jun;55(6):1240-50.
• [13] Rituximab for rheumatoid arthritis-associated large granular lymphocytic leukemia, a retrospective case series. Semin Arthritis Rheum. 2020 Oct;50(5):1109-1113.
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [15] Idiopathic thrombocytopenic purpura (ITP) - new era for an old disease. Rom J Intern Med. 2019 Dec 1;57(4):273-283.
• [16] 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020 Jun;79(6):713-723.
• [17] Update on eosinophilic granulomatosis with polyangiitis. Allergol Int. 2019 Oct;68(4):430-436.
• [18] ClinicalTrials.gov (NCT02383589) A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Rituximab Versus MMF in Patients With Pemphigus Vulgaris. U.S. National Institutes of Health.
• [19] Open-Label Study to Evaluate the Effect of Treatment With Fentanyl Buccal Tablets on Pain Anxiety Symptoms When Used for the Management of Breakthrough Pain
• [20] ClinicalTrials.gov (NCT01841502) Interaction Between Paroxetine and Telaprevir
• [21] Diffuse Large B-Cell Lymphoma and Related Entities. Dtsch Arztebl Int. 2023 Apr 28;120(17):289-296.